Phase 4 N=8 Intravenous Exenatide in Patients With Acute Brain Injury
Brain Injuries
Primary: Percentage of Critically Ill Patients With Acute Brain Injury Achieving Pre-specified Feasibility Criteria — 0; 87.5; 0 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=27 Dexamethasone Plus Virtual Reality Exposure Therapy for PTSD
PTSD
Primary: Change in The Clinician Administered PTSD Scale (CAPS)Scores — -11; -15.22 units on a scale
Phase 3 N=1,401 Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Nonmetastatic Castration-Resistant Prostate Cancer · Prostate Cancer · Cancer of the Prostate
Primary: Metastasis Free Survival (MFS) — 36.6; 14.7 months — p=<0.0001
Phase 2 N=26 Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
Colorectal Neoplasms
Primary: The Number of Participants With Treatment-Related Adverse Events and Serious Adverse Events as a Measure of Safety — 25; 1 Participants
Phase 2 N=391 Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
Prostatic Neoplasms
Primary: Number of Participants With an Event Defining SSE Free Survival - High Dose vs. Standard Dose — 85; 118 Participants
Phase 2 N=18 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
Head and Neck Cancer
Primary: Response Rate — 4 participants
Phase 2 N=11 Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)
Mucopolysaccharidosis IIIB
Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 1; 0; 1 Participants
Phase 3 N=215 A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
Influenza, Human
Primary: Percentage of Participants With Adverse Events — 40.0; 47.3; 25.7; 29.1 percentage of participants
Phase 2 N=41 Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Aggressive Non-Hodgkin Lymphoma
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0 Participants
N/A N=22 Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects
Hepatitis C
Primary: Ratios of Cerebral Metabolites Choline (CH), Myoinisitol (MI) and N-acety Aspartate (NAA)to Creatine (Cr) in 3 Brain Regions Including Basal Ganglia, Frontal Cortex and…
Phase 4 N=101 Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study
Intussusception · Rotavirus Infections
Primary: The Effects of RV1 and RV5 With or Without Other Routine Immunizations on Gastrointestinal Anatomy — 2; 1; 0; 1 Participants — p=0.2
Phase 3 N=302 The Vaginal Health Trial
Atrophy of Vagina · Menopause · Dyspareunia (Female)
Primary: Most Bothersome Symptom (MBS) Severity — -1.2; -1.0; -0.2; -1.4 units on a scale — p=0.25
Phase 3 N=5,377 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia · Childhood B Acute Lymphoblastic Leukemia
Primary: Event-free Survival (EFS) for SR-Average ALL Patients — 83.82; 88.89; 88.34; 90.51 percent probability
N/A N=901 Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men
HIV · Gonorrhea · Chlamydia
Primary: Participants Self-Reporting Condomless Anal Sex at Baseline and 3 Months — 304; 312; 148; 184 Participants — p=0.20
Phase 4 N=110 Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients
Head and Neck Cancer · Acute Pain · Postoperative Pain
Primary: Change in Daily Narcotic Consumption — 1.60; 1.59 mg/hour